SMI helps pharmaceutical, biotechnology and diagnostic companies better understand the disease process early in the development process, as opposed to after the drug or diagnostic product has been developed.

Rapidly Test and Validate Products for the Market

By stratifying the disease and then stratifying the patient, Strategic Medicine can identify the subtypes of disease as well as the subtypes of patients from which their research can be focused. This knowledge enables companies to more rapidly test and validate new products and bring them to market. Additionally, it makes those products better-labeled in terms of how they should be applied to clinical problems.

Identify the Risk of Off Target Effects

Later stage drug failures frequently occur because of lack of understanding of the complexity of the disease or the population. Strategic Medicine’s disease modeling services can help drug companies identify the risk of off target effects so that they can be incorporated into altered labeling, improved clinical trial design, or review of the results from trials or post marketing surveillance.